- Home
- PHAR vs CRI Comparison
PHAR vs CRI Comparison
Compare PHAR & CRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- CRI
- Stock Information
- Founded
- PHAR 1988
- CRI 1865
- Country
- PHAR Netherlands
- CRI United States
- Employees
- PHAR N/A
- CRI N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- CRI Apparel
- Sector
- PHAR Health Care
- CRI Consumer Discretionary
- Exchange
- PHAR Nasdaq
- CRI Nasdaq
- Market Cap
- PHAR 951.7M
- CRI 1.0B
- IPO Year
- PHAR N/A
- CRI 2003
- Fundamental
- Price
- PHAR $13.14
- CRI $32.03
- Analyst Decision
- PHAR Strong Buy
- CRI Sell
- Analyst Count
- PHAR 3
- CRI 4
- Target Price
- PHAR $30.00
- CRI $29.50
- AVG Volume (30 Days)
- PHAR 11.0K
- CRI 1.3M
- Earning Date
- PHAR 11-06-2025
- CRI 10-27-2025
- Dividend Yield
- PHAR N/A
- CRI 3.18%
- EPS Growth
- PHAR N/A
- CRI N/A
- EPS
- PHAR N/A
- CRI 2.45
- Revenue
- PHAR $339,836,000.00
- CRI $2,832,687,000.00
- Revenue This Year
- PHAR $17.70
- CRI $1.26
- Revenue Next Year
- PHAR $12.25
- CRI N/A
- P/E Ratio
- PHAR N/A
- CRI $12.81
- Revenue Growth
- PHAR 22.44
- CRI N/A
- 52 Week Low
- PHAR $7.31
- CRI $23.38
- 52 Week High
- PHAR $17.08
- CRI $58.13
- Technical
- Relative Strength Index (RSI)
- PHAR 42.37
- CRI 54.72
- Support Level
- PHAR $13.08
- CRI $31.05
- Resistance Level
- PHAR $14.10
- CRI $34.94
- Average True Range (ATR)
- PHAR 0.52
- CRI 1.85
- MACD
- PHAR -0.16
- CRI 0.09
- Stochastic Oscillator
- PHAR 0.00
- CRI 50.48
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About CRI Carter's Inc.
Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.